SANTA FE, N.M.--(BUSINESS WIRE)--Advanced Influenza Technologies, Inc. (AITI), a wholly owned subsidiary of CytoDyn, Inc. (Pink Sheets: CYDY), recently received the results of a comparative study of the effectiveness of DNA vaccines for the bird flu. As is customary, the study was conducted on mice in a biosafety level 3 laboratory. Results from the study show why AITI’s proprietary method of vaccination could help all DNA vaccines work better, turning competitors into customers for a deeper market penetration.
